(Press-News.org) DURHAM, N.C. - How most babies are protected from acquiring HIV from their infected mothers has been a matter of scientific controversy. Now researchers at Duke Medicine provide new data identifying an antibody response that had long been discounted as inadequate to confer protection.
Mother-to-child transmissions account for about 250,000 HIV infections per year worldwide, despite greatly expanded access to antiretroviral drug regimens that can interrupt transmission into low-resource settings. Ongoing problems with access to the drugs, late initiation of the drug regimens during pregnancy, and acute maternal infection during pregnancy and breastfeeding all contribute to the ongoing infant transmission.
Even in the absence of antiretroviral drug regimens, however, the majority of newborns are naturally protected against HIV, despite chronic virus exposure. The Duke research team sought to define what is different in the babies who become infected compared to those who don't.
"We know that mothers pass antibodies to fetuses in-utero, but a true understanding of how maternal antibodies were contributing to protection had never been established," said Sallie Permar, M.D., Ph.D., associate professor of pediatrics at Duke and lead author of a study published online June 8, 2015, in the Journal of Clinical Investigation.
Permar and colleagues at the Duke Human Vaccine Institute and the Fred Hutchison Cancer Research Center analyzed data from a U.S. study in the 1990s that predated therapies such as AZT. The study included mothers and babies, yielding information about risk factors and transmissions in a pre-treatment environment.
By profiling the immune responses of mothers in this early study, the researchers were able to pinpoint the differences between those who transmitted the virus to their infants, and those who did not.
Among mothers whose babies were shielded from infection, they found a strong antibody response to a particular region on the HIV virus envelope (the HIV envelope third variable or V3 loop) that has been considered too variable and too inaccessible to be a relevant target for a neutralizing antibody.
"That was very surprising," Permar said, "because this type of weak neutralizing antibody response, which had previously been thought to be inconsequential for HIV transmission, could potentially be effective in preventing mother-to-child transmission. And there are current HIV vaccine candidates, such as recombinant HIV envelope protein immunization, in early-stage clinical testing that can elicit this type of response."
Permar said the team's study raises a compelling question about why the V3 neutralizing antibody response seems to be enough to reduce mother-to-child transmission, yet is not protective in other modes of HIV transmission.
"The difference in mother-to-infant transmission might be that the infant is only being exposed to the mother's virus, and the infant is born with antibodies that are transferred from the mother," Permar said. "The presence of antibodies that were raised against the mother's virus prior to exposure to the same virus makes the infant transmission setting very different from that of other modes of HIV transmission. So how well the mother's antibody can neutralize her own virus could be the key to whether the baby is infected."
Permar said additional research at Duke will focus on testing newer experimental HIV vaccines to raise this potentially protective antibody response in mothers to neutralize her virus and thereby protect the baby.
"We hope this will be a major clue to making a vaccine to effectively prevent all mother-to-child HIV transmission, since these antibodies are the type that our current experimental HIV vaccines can boost," said M. Anthony Moody, M.D., a co-author and chief medical officer in the Duke Human Vaccine Institute. "For protecting unborn and newborn children, we may be closer to testing a vaccine that can induce this type of common HIV-specific antibody response for its ability to protect infants than previously thought."
INFORMATION:
In addition to Moody and Permar, study authors include Youyi Fong; Nathan Vandergrift; Genevieve G. Fouda; Peter Gilbert; Robert Parks; Frederick H. Jaeger; Justin Pollara; Amanda Martelli; Brooke E. Liebl; Krissey Lloyd; Nicole L. Yates; R. Glenn Overman; Xiaoying Shen; Kaylan Whitaker; Haiyan Chen; Jamie Pritchett; Erika Solomon; Emma Friberg; Dawn J. Marshall; John F. Whitesides; Thaddeus C. Gurley; Tarra Von Holle; David R. Martinez; Fangping Cai; Amit Kumar; Shi-Mao Xia; Xiaozhi Lu; Raul Louzao; Samantha Wilkes; Saheli Datta; Marcella Sarzotti-Kelsoe; Hua-Xin Liao; Guido Ferrari; S. Munir Alam; David C. Montefiori; Thomas N. Denny; Georgia D. Tomaras; Feng Gao; and Barton Haynes.
Funding included grants from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health (5-UM1-AI100645, 5-P30-AI064518).
At least two and a half million more workers will be needed to provide long-term care to older people in the United States between now and 2030, according to a study by UC San Francisco researchers published in the June 2015 issue of Health Affairs.
The study authors predict that there will be little effect on this demand for new workers even if long-term care use among different racial and ethnic groups changes significantly or if there is a major shift from institutional care to home-based care.
'Even if 20 percent of elderly patients move out of nursing homes into ...
The June issue of Health Affairs, a variety issue, includes articles examining how health care markets function, both in the United States and elsewhere.
One of the studies in the issue is by Zachary Wagner of the University of California, Berkeley, and coauthors, titled "PEPFAR Funding Associated With An Increase In Employment Among Males In Ten Sub-Saharan African Countries." It examines the economic impact of the President's Emergency Plan for AIDS Relief--or PEPFAR--in sub-Saharan Africa. PEPFAR has provided over 6.7 million people infected with HIV access to antiretroviral ...
Stem cell transplantation is used to treat hematologic malignancies, such as leukemia. Patients that receive donor cells are at risk of developing graft-versus host disease (GVHD). This potentially fatal complication results when naive T cells generated from the graft promote an immune response that attacks the recipient's tissues. Prophylactic treatment with immunosuppressive drugs is currently used to limit GVHD but does not reliably prevent disease. In mouse models, depletion of naive T cells from the stem cell graft prior to transplant reduces the occurrence and severity ...
New research from Brigham and Women's Hospital finds that physician characteristics are the strongest predictor of whether a patient will be referred to hospice care.
Individual physicians are widely believed to influence the kind of care their patients receive at the end of life, but to date, there is little scientific evidence to support this belief. New research from Brigham and Women's Hospital (BWH) indicates that the individual physician a patient sees is the strongest known predictor of whether or not he or she will enroll in hospice care, outweighing other known ...
A new study by NYU Wagner Dean and Professor of Public Service Sherry A. Glied and two additional researchers sees little evidence to support the belief that healthcare workers' wage levels are responsible for the rising cost of health care services in the U.S. Effective cost containment will require not wage reductions alone, but broad productivity gains derived from the use of fewer or less-skilled employees to produce any given service, the study concludes.
Published today (June 8) in the June edition of the peer-reviewed journal Health Affairs, the paper by ...
Researchers at Trinity College Dublin and Mount Sinai in New York have just published new research which for the first time provides strong evidence on the economic benefits of early palliative care intervention for people with an advanced cancer diagnosis. Their findings were published today in the highly esteemed international peer reviewed Journal of Clinical Oncology.
Previous research has shown the clinical benefits of early palliative care, but this new study robustly demonstrated how early access to expert palliative care decision making resulted in very significant ...
PHILADELPHIA-- Using a simple blood test to measure the T lymphocyte count in donors for stem cell transplants may help identify the best match for patients in need of an allogeneic stem cell transplant, suggests a new study in the Journal of Clinical Oncology from researchers at the Abramson Cancer Center (ACC) of the University of Pennsylvania. Typically, matched siblings have been preferred over unrelated donors. This study shows that older patients who received stem cells from younger, unrelated donors with higher numbers of so-called killer T cells (CD8 cells) had ...
New York, NY-- Earlier introduction of palliative care for patients hospitalized with advanced cancer is associated with lower hospital costs, according to a new study published in the Journal of Clinical Oncology. The findings support a growing body of evidence that suggests that early provision of palliative care not only enhances the quality of medical care received by patients and families with serious illness, but does so at a lower cost than traditional oncologic care.
The observational study, funded by the National Cancer Institute and National Institute for Nursing ...
New Haven, Conn. -- Gay and bisexual men living in European countries with strong attitudes and policies against homosexuality are far less likely to use HIV-prevention services, test for HIV, and discuss their sexuality with health providers, according to research led by Yale School of Public Health (YSPH).
The study is published online in the journal AIDS.
Attitudes about homosexuality vary greatly across Europe, noted YSPH associate professor and lead author John Pachankis and his colleagues. The research team wanted to investigate the impact of homophobia on gay and ...
CHICAGO -- A toxin secreted by Vibrio vulnificus, a water and food-borne bacteria that can cause rapidly lethal infections in persons with liver disease, has potential to prevent the growth of tumors, according to a new study by Northwestern Medicine scientists.
Karla Satchell, a professor in microbiology-immunology at Northwestern University Feinberg School of Medicine, and her team demonstrated in a paper in Nature Communications, that a multifunctional-autoprocessing repeats-in-toxin (MARTX) protein from Vibrio vulnificus can inhibit tumor cell growth by cutting the ...
